LUCIER PHARMACEUTICALS INC.

About Lucier Pharmaceuticals

To address unmet medical needs, Lucier Pharmaceuticals is developing novel drugs toward effectively managing microvascular diseases.

Our drug candidates are based on novel scientifc findings from one Texas A&M University research lab, one patent application is pending.

Pipeline

Preclincial development
LU-1001: injectable small molecular inhibitor to improve the diagnosis of coroanry microvascular dysfunction/disease (CMD).
LU-1002: oral small molecular inhibitor for treating microvascular diseases.

Meet Our Team

Guangrong Lu, MBBS.

Co-inventor

Founder and CEO

Lih Kuo, PhD.

Co-inventor

Regents Professor, Scientific Advisor

E.L. Berryman

Reg. Toxicologist

Pre-clinical Development Advisor

Lee Schalop, MD.

Angel Investor and Entrepreneur

Business Advisor

Some videos by medical professionals maybe helpful for you to better understand microvascular dysfunction

https://www.youtube.com/watch?v=0Hx51knjCSg
https://www.youtube.com/watch?v=wOcsbpOyU38
https://www.youtube.com/watch?v=kXBognpmYlg